These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2263 related articles for article (PubMed ID: 18579750)

  • 1. TEAD mediates YAP-dependent gene induction and growth control.
    Zhao B; Ye X; Yu J; Li L; Li W; Li S; Yu J; Lin JD; Wang CY; Chinnaiyan AM; Lai ZC; Guan KL
    Genes Dev; 2008 Jul; 22(14):1962-71. PubMed ID: 18579750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein.
    Zhao B; Kim J; Ye X; Lai ZC; Guan KL
    Cancer Res; 2009 Feb; 69(3):1089-98. PubMed ID: 19141641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
    Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
    Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
    Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling.
    Ota M; Sasaki H
    Development; 2008 Dec; 135(24):4059-69. PubMed ID: 19004856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YAP represses the TEAD-NF-κB complex and inhibits the growth of clear cell renal cell carcinoma.
    Li Z; Su P; Yu M; Zhang X; Xu Y; Jia T; Yang P; Zhang C; Sun Y; Li X; Yang H; Ding Y; Zhuang T; Guo H; Zhu J
    Sci Signal; 2024 Jul; 17(843):eadk0231. PubMed ID: 38954637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Abl antagonizes the YAP oncogenic function.
    Keshet R; Adler J; Ricardo Lax I; Shanzer M; Porat Z; Reuven N; Shaul Y
    Cell Death Differ; 2015 Jun; 22(6):935-45. PubMed ID: 25361080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
    Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
    EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutual dependence of the MRTF-SRF and YAP-TEAD pathways in cancer-associated fibroblasts is indirect and mediated by cytoskeletal dynamics.
    Foster CT; Gualdrini F; Treisman R
    Genes Dev; 2017 Dec; 31(23-24):2361-2375. PubMed ID: 29317486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mask is required for the activity of the Hippo pathway effector Yki/YAP.
    Sansores-Garcia L; Atkins M; Moya IM; Shahmoradgoli M; Tao C; Mills GB; Halder G
    Curr Biol; 2013 Feb; 23(3):229-35. PubMed ID: 23333314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
    Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
    Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.
    Liu J; Li J; Li P; Wang Y; Liang Z; Jiang Y; Li J; Feng C; Wang R; Chen H; Zhou C; Zhang J; Yang J; Liu P
    Sci Rep; 2017 Feb; 7():42125. PubMed ID: 28169360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis.
    Zhou Y; Huang T; Cheng AS; Yu J; Kang W; To KF
    Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26805820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural insights into the YAP and TEAD complex.
    Li Z; Zhao B; Wang P; Chen F; Dong Z; Yang H; Guan KL; Xu Y
    Genes Dev; 2010 Feb; 24(3):235-40. PubMed ID: 20123905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway.
    Mo JS; Meng Z; Kim YC; Park HW; Hansen CG; Kim S; Lim DS; Guan KL
    Nat Cell Biol; 2015 Apr; 17(4):500-10. PubMed ID: 25751140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.
    Liu-Chittenden Y; Huang B; Shim JS; Chen Q; Lee SJ; Anders RA; Liu JO; Pan D
    Genes Dev; 2012 Jun; 26(12):1300-5. PubMed ID: 22677547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tead2 expression levels control the subcellular distribution of Yap and Taz, zyxin expression and epithelial-mesenchymal transition.
    Diepenbruck M; Waldmeier L; Ivanek R; Berninger P; Arnold P; van Nimwegen E; Christofori G
    J Cell Sci; 2014 Apr; 127(Pt 7):1523-36. PubMed ID: 24554433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain.
    Lamar JM; Stern P; Liu H; Schindler JW; Jiang ZG; Hynes RO
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):E2441-50. PubMed ID: 22891335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
    Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
    FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mask proteins are cofactors of Yorkie/YAP in the Hippo pathway.
    Sidor CM; Brain R; Thompson BJ
    Curr Biol; 2013 Feb; 23(3):223-8. PubMed ID: 23333315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 114.